Helixmith Co., Ltd.   Report issue

For profit Phase 3
Founded: Seoul Korea, Republic of (1996)

Organization Overview

First Clinical Trial
2020
NCT04469270
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Helixmith Co., Ltd.